References
- Ancuceanu R, Dinu M, Arama C. 2013. Weight loss food supplements: adulteration and multiple quality issues in two products of Chinese origin. Farmacia. 61:28–44.
- Australian Goverment. 2007. Safety Information/alerts/Lida Daidaihua Slimming Capsules; 2007 Oct 19 [Internet]. Symonston: Department of Health Therapeutic Goods Administration; [cited 2013 Nov 13]. Available from: http://www.tga.gov.au/safety/alerts-medicine-lida-071019.htm
- Barberich TJ. 2005. Methods of treating, preventing and managing a sleep disorder using (S)-didesmethylsibutramine. Pub.No.: US2005/0228052 A1. 2005 Oct 13. United States Patent Application Publication.
- Chen SPL, Tang MHY, Ng SW, Poon WT, Chan AYW, Mak TWL. 2010. Psychosis associated with usage of herbal slimming products adulterated with sibutramine: a case series. Clin Toxicol. 48:832–838.
- Chen Y, Zhao L, Lu F, Yu Y, Chai Y, Wu Y. 2009. Determination of synthetic drugs used to adulterate botanical dietary supplements using QTRAP LC-MS/MS. Food Addit Contam: Part A. 26:595–603.
- Chong CSY. 2010. Psychosis related to the use of sibutramine disguised as over-the-counter herbal weight loss remedies; a report of two patients. East Asian Arch Psychiatry. 20:18–189.
- Cohen PA, Ernst E. 2010. Safety of herbal supplements: aguide for cardiologists. Cardiovasc Ther. 28:246–253.
- De Carvalho LM, Cohen PA, Silva CV, Moreira APL, Falcão TM, Dal Molin TR, Zemolin G, Martini M. 2012. A new approach to determining pharmacologic adulteration of herbal weight loss products. Food Addit Contam: Part A. 29:1661–1667.
- De Carvalho LM, Martini M, Moreira APL, de Lima APS, Correia D, Falcão T, Garcia SC, de Bairros AV, do Nascimento PC, Bohrer D. 2011. Presence of synthetic pharmaceuticals as adulterants in slimming phytotherapeutic formulations and their analytical determination. Forensic Sci Int. 204:6–12.
- Ding L, Hao X, Huang X, Zhang S. 2003. Simultaneous determination of sibutramine and its N-desmethyl metabolites in human plasma by liquid chromatography-electrospray ionization-mass spectrometry. Method and clinical applications. Anal Chim Acta. 492:241–248.
- Dunn JD, Gryniewicz-Ruzicka CM, Kauffman JF, Westenberger BJ, Buhse LF. 2011. Using a portable ion mobility spectrometer to screen dietary supplements for sibutramine. J Pharmeceut Biomed. 54:469–474.
- Dunnick JK, Hailey JR. 1996. Phenolphthalein exposure causes multiple carcinogenic effects in experimental model systems. Cancer Res. 56:4922–4926.
- [EC] European Commission. 2013. List of referrals for human medicinal products [Internet]. Brussels: DG Health & Consumers; [cited 2013 Nov 8]. Available from: http://ec.europa.eu/health/documents/community-register/html/ho1043.htm
- [EFSA] European Food Safety Authority. 2005. Opinion of the Scientific Committee on a request from EFSA related to a harmonised approach for risk assessment of substances which are both genotoxic and carcinogenic [Internet]. Parma: EFSA. The EFSA Journal No. 282; p. 1–31; [cited 2013 Nov 11]. Available from: http://www.efsa.europa.eu/en/efsajournal/doc/282.pdf
- [EFSA] European Food Safety Authority. 2012. Guidance on selected default values to be used by the EFSA Scientific Committee, Scientific Panels and Units in the absence of actual measured data [Internet]. Parma: EFSA. The EFSA Journal No. 10(3):2579; [cited 2013 Nov 26]. Available from: http://www.efsa.europa.eu/en/efsajournal/doc/2579.pdf
- [EMA] European Medicines Agency. 1997. Position paper on the genotoxic and carcinogenetic potential of phenolphthalein [Internet]. London: European Medicines Agency, CPMP/818/97; [cited 2013 Nov 11]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Position_statement/2009/09/WC500003148.pdf
- [EMA] European Medicines Agency. 2002. Opinion following an article 31 referral: Sibutramine. 2 December 2002 CPMP/4514/02/Final. Committee for Proprietary Medicinal Products [Internet]. London: European Medicines Agency; [cited 2013 Nov 26]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Sibutramine_31/WC500013923.pdf
- [EMA] European Medicines Agency. 2007. European public assessment report (EPAR) Acomplia, last updated 10–2007 [Internet]. London: European Medicines Agency; [cited 2013 Nov 11]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000666/WC500021282.pdf
- [EMA] European Medicines Agency. 2009. Public statement on Acomplia (rimonabant). Withdrawal of the marketing authorization in the European Union. London 30 January 2009/EMEA/39457/2009 [Internet]. London: European Medicines Agency; [cited 2013 Nov 13]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/11/WC500012189.pdf
- [EMA] European Medicines Agency. 2010a. European Medicines Agency recommends suspension of marketing authorisations for sibutramine. EMA/39408/2010 [Internet]. London: European Medicines Agency; [cited 2013 Nov 8]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/01/WC500069995.pdf
- [EMA] European Medicines Agency. 2010b. Questions and answers on the suspension of medicines containing sibutramine. EMA/808179/2009 rev, EMEA/H/A-107/1256; 2010 Aug 6 [Internet]. London: European Medicines Agency; [cited 2013 Nov 12]. Available from: http://www.emea.europa.eu/docs/en_GB/document_library/Referrals_document/Sibutramine_107/WC500094238.pdf
- [EMA] European Medicines Agency. 2013. Acomplia. Medicinal products no longer authorized [Internet]. London: European Medicines Agency; [cited 2013 Nov 12]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_All_Authorised_presentations/human/000666/WC500021283.pdf
- [EPA] Environmental Protection Agency. 2013. BMDS download Page [Internet]. Washington DC: United States Environmental Protection Agency; [cited 2013 Nov 4, 2013]. Available from: http://www.epa.gov/ncea/bmds/dwnldu.html
- [FDA] Food and Drug Administration. 2013. Questions and answers about FDA’s initiative against contaminated weight loss products. Page Last Updated: 09/03/2013 [Internet]. Silverspring: US Food and Drug Administration; [cited 2013 Nov 13]. Available from: http://www.fda.gov/Drugs/ResourcesForYou/Consumers/QuestionsAnswers/ucm136187.htm
- Felter SP, Conolly RB, Bercu JP, Bolger PM, Boobis AR, Bos PM, Carthew P, Doerrer NG, Goodman JI, Harrouk WA, Kirkland DJ, Lau SS, et al. 2011. A proposed framework for assessing risk from less-than-lifetime exposures to carcinogens. Crit Rev Toxicol. 41:507–544.
- Fil L, Decena E, Patel R, Levy D. 2011 Aug 4. Dying to lose weight. Emergency Medicine News [Internet]; [cited 2013 Nov 11]. Available from: http://journals.lww.com/em-news/Fulltext/2011/08041/Dying_to_Lose_Weight.3.aspx
- Glick SD, Haskew RE, Maisonneuve IM, Carlson JN, Jerussi TP. 2000. Enantioselective behavioral effects of sibutramine metabolites. Eur J Pharmacol. 397:93–102.
- Health Canada. 2006. Health Canada advises consumers not to use Super Fat Burning and LiDa Daidaihua Slimming Capsules for weight loss; 2006 Apr 5 [Internet]. Ottawa; Health Canada; [cited 2013 Nov 13]. Available from: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2006/13090a-eng.php
- [IARC] International Agency for Research on Cancer. 2000. Phenolphthalein [Internet]. Lyon; International Agency for Research on Cancer, Monographs on the evaluation on the carcinogenic risks to humans, volume 76; [cited 2013 Nov 11]. Available from: http://monographs.iarc.fr/ENG/Monographs/vol76/mono76-15.pdf
- [IGZ] Inspectie voor de Gezondheidszorg. 2010. Waarschuwing voor afslankmiddel Green Coffee 800. Nieuwsbericht 6-8-2010 [Internet]. Utrecht: Health Care Inspectorate; [cited 2013 Nov 13]. Available from: http://www.igz.nl/actueel/nieuws/waarschuwingvoorafslankmiddelgreencoffee800.aspx
- Ioannides-Demos LL, Proietto J, Tonkin AM, McNeil JJ. 2006. Safety of drug therapies used for weight loss and treatment of obesity. Drug Safety. 29:277–302.
- Jerussi TP, Senayake CH, Fang QK. 2001. Methods of treating and preventing attention deficit disorders. Patent No. US 6,331,571 B1. Date of patent: Dec. 18, 2001.
- Joint FAO/WHO Expert Committee on Food Additives. 2005. Summary and conclusions of the sixty-fourth meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA); 2005 Feb 8–17; Rome [Internet]. [cited 2013 Nov 15]. Available from: ftp://ftp.fao.org/es/esn/jecfa/jecfa64_summary.pdf
- Jordan MA, Haywood T. 2007. Evaluation of Internet websites marketing herbal weight-loss supplements to consumers. J Altern Complement Med. 13:1035–1043.
- Kang MJ, Song WH, Shim BH, Oh SY, Lee HY, Chung EY, Sohn Y, Lee J. 2010b. Pharmacologically active metabolites of currently marketed drugs: potential resources for new drug discovery and development. Yakugaku Zasshi. 130:1325–1337.
- Kang W, Bae K, Noh K. 2010a. Enantioselective determination of sibutramine and its active metabolites in human plasma. J Pharmaceut Biomed. 51:264–267.
- [Lareb] Netherlands Pharmacovigilance Centre. 2013. Netherlands Pharmacovigilance Centre Lareb. [Internet]; [cited 2013 Nov 13]. Available from: http://www.lareb.nl/
- Lee J, Teoh T, Lee T-S. 2008. Catatonia and psychosis associated with sibutramine: a case report and pathophysiologic correlation. J Psychosom Res. 64:107–109.
- Litvan L, Alcoverro-Fortuny Ò. 2007. Sibutramine and Psychosis. J Clin Psychopharm. 27:726–727.
- Martin M, Schlabach G, Shibinski K. 1998. The use of non-prescription weight loss products among female basketball, softball, and volleyball athletes from NCAA Division I Institutions; issues and concerns. J Athl Training. 33:41–44.
- [MHRA] Medicines and Healthcare Products Regulatory Agency. 2010. US Food and Drug Administration (FDA) issue warning to consumers about slimming pills containing undeclared pharmaceuticals. page last modified July 7, 2010 [Internet]. London: Medicines and Healthcare Products Regulatory Agency (MHRA); [cited 2013 Nov 11]. Available from: http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Herbalmedicines/Herbalsafetyupdates/Allherbalsafetyupdates/CON038761
- Müller D, Weinmann W, Hermanns-Clausen M. 2009. Chinese slimming capsules containing sibutramine sold over the Internet. Dtsch Arztebl Int. 106:218–222.
- Nisoli E, Carruba MO. 2000. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev. 1:127–139.
- [NTP] National Toxicology Program. 1996. Toxicology and Carcinogenesis Studies of Phenolphthalein in F344/N Rats and B6C3F1 Mice (Feed Studies). Technical Report Series no. 465. 354 pp. Research Triangle Park, NC: National Toxicology Program; [cited 2013 Nov 11]. Available from: http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr465.pdf#search=technical%20report%20series%20465%20phenolphthalein
- [NTP] National Toxicology Program. 2011. Phenolphthalein [Internet]. Report on Carcinogens, Twelfth Edition (2011). NC; National Toxicology Program, National Institute of Environmental Health Sciences; [cited 2013 Nov 11]. Available from: http://ntp.niehs.nih.gov/ntp/roc/twelfth/profiles/Phenolphthalein.pdf#search=report%20on%20carcinogens%20phenolphthalein
- Ozdemir B, Sahin I, Kapucu H, Celbis O, Karakoc Y, Erdogan S, Onal Y. 2013. How safe is the use of herbal weight-loss products sold over the Internet? Hum Exp Toxicol. 32:101–106.
- Padwal RS, Majumdar SR. 2007. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 369:71–77.
- Phattanawasin P, Sotanaphun U, Sukwattanasinit T, Akkarawaranthorn J, Kitchaiya S. 2012. Quantitative determination of sibutramine in adulterated herbal slimming formulations by TLC-image analysis method. Forensic Sci Int. 219:96–100.
- Reeuwijk NM, Venhuis BJ, de Kaste D, Hoogenboom LAP, Rietjens IMCM, Martena MJ. 2013. Sildenafil and analogous phosphodiesterase type 5 (PDE-5) inhibitors in herbal food supplements sampled on the Dutch market. Food Addit Contam: Part A. 30:2027–2034.
- [RIVM] Rijksinstituur voor Volksgezondheid en Milieu. 2009. Trends in drug substances detected in illegal weight-loss medicines and dietary supplements. A 2002–2007 survey and health risk analysis [Internet]. Report 370030002/2009. B.J. Venhuis et al. Bilthoven: RIVM; [cited 2013 Nov 9]. Available from: http://www.rivm.nl/bibliotheek/rapporten/370030002.pdf
- Stypułkowska K, Błażewicz A, Maurin J, Sarna K, Fijałek Z. 2011. X-ray powder diffractometry and liquid chromatography studies of sibutramine and its analogues content in herbal dietary supplements. J Pharmaceut Biomed. 56:969–975.
- Taflinski T, Chojnacka J. 2000. Sibutramine-associated psychotic episode. Am J Psychiat. 157:2057–2058. Available from: http://ajp.psychiatryonline.org/article.aspx?articleid=174507
- Tang MHY, Chen SPL, Ng SW, Chan AYW, Mak TWL. 2011. Case series on a diversity of illicit weight-reducing agents: from the well known to the unexpected. Br J Clin Pharmacol. 71:250–253.
- Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S. 2005. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 365:1389–1397.
- Van Hunsel F, van Grootheest K. 2011. Bijwerkingen afslankmiddel, vervuild met sibutramine. Ned Tijdschr Geneeskd. 155:A3695.
- Vaysse J, Balayssac S, Gilard V, Desoubdzanne D, Malet-Martino M, Martino R. 2010. Analysis of adulterated herbal medicines and dietary supplements marketed for weight loss by DOSY 1H-NMR. Food Addit Contam: Part A. 27:903–916.
- Venhuis BJ, Vredenbregt MN, Kaun N, Maurin JK, Fijałek Z, de Kaste D. 2011. The identification of rimonabant polymorphs, sibutramine and analogues of both in counterfeit Acomplia bought on the Internet. J Pharm Biomed. 54:21–26.
- Venhuis BJ, Zwaagstra ME, Keizers PHJ, de Kaste D. 2013. Dose-to-dose variations with single packages of counterfeit medicines and adulterated dietary supplements as a potential source of false negatives and inaccurate health risk assessments [Internet]. J Pharm Biomed; [cited 2013 Nov 29]. Available from: http://dx.doi.org/doi:10.1016/j.jpba.2013.10.038
- Venhuis BJ, Zwaagstra ME, Keizers PHJ, de Kaste D. 2014. Dose-to-dose variations with single packages of counterfeit medicines and adulterated dietary supplements as a potential source of false negatives and inaccurate health risk assessments. J Pharm Biomed. 89:158–165.
- Wang J, Chen B, Yao S. 2008. Analysis of six synthetic adulterants in herbal weight-reducing dietary supplements by LC electrospray ionization-MS. Food Addit Contam: Part A. 25:822–830.
- Waszkiewicz N, Zalewska-Szajda B, Szajda SD, Simonienko K, Zalewska A, Szulc A, Ładny JR, Zwierz K. 2012. Sibutramine-induced mania as the first manifestation of bipolar disorder. BMC Psychiatry. 12:43.
- WHO. 2013. Obesity and overweight. Fact sheet N°311. Updated March 2013 [Internet]. Geneva: World Health Organization; [cited 2013 Nov 8]. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/
- Wilfley DE, Crow SJ, Hudson JI, Mitchell JE, Berkowitz RI, Blakesley V, Walsh BT. 2007. Efficacy of sibutramine for the treatment of Binge Eating Disorder: A Randomized Multicenter Placebo-Controlled Double-Blind Study. Am J Psychiatry. 165:51–58.
- Yuen YP, Lai CK, Poon WT, Ng SW, Chan AYW, Mak TWL. 2007. Adulteration of over-the-counter slimming products with pharmaceutical analogues – an emerging threat. Hong Kong Med J. 13:216–220.
- Zou P, Oh SS-Y, Kiang K-H, Low M-Y, Bloodworth BC. 2007. Detection of sibutramine, its two metabolites and one analogue in a herbal product for weight loss by liquid chromatography triple quadrupole mass spectrometry and time-of-flight mass spectrometry. Rapid Commun Mass Spectrom. 21:614–618.